Showing results (71-80 of 113) with videos related to

Sort By:
Pageof 12
Leukemia|April 28, 2006
Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(phi)-LMC GROUP)F E Nicolini, S Corm, Q-H Lê, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|September 13, 2011
Invasive aspergillosis: an important risk factor on the short- and long-term survival of acute myeloid leukemia (AML) patientsM Michallet, T Bénet, M Sobh, et al.
Cancer Medicine|July 28, 2019
Incidence and outcome of BCR-ABL mutated chronic myeloid leukemia patients who failed to tyrosine kinase inhibitorsGabriel Etienne, Stéphanie Dulucq, Françoise Huguet, et al.
Experimental Hematology|September 9, 2018
Ponatinib evaluation and safety in real-life chronic myelogenous leukemia patients failing more than two tyrosine kinase inhibitors: the PEARL observational studyMaël Heiblig, Delphine Rea, Marie-Lorraine Chrétien, et al.
Leukemia Research|December 15, 2010
The addition of daunorubicin to imatinib mesylate in combination with cytarabine improves the response rate and the survival of patients with myeloid blast crisis chronic myelogenous leukemia (AFR01 study)Bénédicte Deau, Franck E Nicolini, Joelle Guilhot, et al.
Cancer|April 8, 2017
Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutationFranck E Nicolini, Grzegorz W Basak, Dong-Wook Kim, et al.
Leukemia|February 22, 2024
Chronic myeloid leukemia diagnosed in pregnancy: management and outcome of 87 patients reported to the European LeukemiaNet international registryEkaterina Chelysheva, Jane Apperley, Anna Turkina, et al.
Cancer|January 15, 2015
Final analysis of the efficacy and safety of omacetaxine mepesuccinate in patients with chronic- or accelerated-phase chronic myeloid leukemia: Results with 24 months of follow-upJorge E Cortes, Hagop M Kantarjian, Delphine Rea, et al.
British Journal of Haematology|April 2, 2023
Efficacy and safety of nilotinib in chronic myeloid leukaemia patients who failed to achieve a treatment-free remission period after imatinib discontinuation: Results of the French Nilo post-STIM studyStéphanie Dulucq, Françoise Rigal-Huguet, Franck E Nicolini, et al.
American Journal of Hematology|September 2, 2022
Ponatinib after failure of second-generation tyrosine kinase inhibitor in resistant chronic-phase chronic myeloid leukemiaHagop M Kantarjian, Elias Jabbour, Michael Deininger, et al.
Pageof 12